A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) in patients with a new or recurrent episode of depressio
Not Applicable
Completed
- Conditions
- Mental and Behavioural DisordersDepressive episodeDepression
- Registration Number
- ISRCTN63565713
- Lead Sponsor
- axdale Ltd (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
1. Written informed consent
2. Diagnosis of major depressive disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth edition [DSM-IV])
3. Score of between and including 16 and 25 on the Hamilton Depression Rating Scale (HDRS)
4. No treatment with any antidepressant medication (including St John's Wort) in the last 12 weeks from the date of Visit 0 (screen)
5. Male or female of any race aged 18-75
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration